Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 20/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | JAK3 | P52333 | 1/20 | 0.79 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29926978 | 1.00 | ERBB2 (1.00) | ERBB2EGFRJAK3ERBB4 | |
| SCHEMBL19181013 | 1.00 | ERBB2 (1.00) | ERBB2EGFRJAK3ERBB4 | |
| SCHEMBL29434938 | 1.00 | ERBB2 (1.00) | ERBB2EGFRJAK3ERBB4 | |
| SCHEMBL19180965 | 0.96 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL19180964 | 0.96 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL19181605 | 0.94 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL31409138 | 0.94 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL19182285 | 0.94 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL19182284 | 0.94 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL31409145 | 0.94 | ERBB2 (1.00) | ERBB2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3590516-B1 | ANTITUMOR-EFFECT ENHANCER USING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2025-09-03 | — | — | EP | claimed |
| EP-3845537-B1 | CRYSTAL OF PYRAZOLO[3,4-D]PYRIMIDINE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2025-07-30 | — | — | EP | claimed |
| US-12215109-B2 | Crystal of pyrazolo[3,4-d]pyrimidine | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-02-04 | — | — | US | claimed |
| US-12186320-B2 | Therapeutic agent containing pyrazolo[3,4-d]pyrimidine compound as active ingredient | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-01-07 | — | — | US | claimed |
| EP-3845231-B1 | THERAPEUTIC AGENT CONTAINING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | TAIHO PHARMACEUTICAL CO LTD (JP) | 2025-01-01 | — | — | EP | claimed |
| US-11696917-B2 | Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-07-11 | — | — | US | claimed |
| US-20210332056-A1 | CRYSTAL OF PYRAZOLO[3,4-D]PYRIMIDINE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-10-28 | — | — | US | claimed |
| US-20210252000-A1 | THERAPEUTIC AGENT CONTAINING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-08-19 | — | — | US | claimed |
| EP-3845537-A1 | CRYSTAL OF PYRAZOLO[3,4-D]PYRIMIDINE | Taiho Pharmaceutical Co., Ltd. (JP) | 2021-07-07 | — | — | EP | claimed |
| EP-3845231-A1 | THERAPEUTIC AGENT CONTAINING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2021-07-07 | — | — | EP | claimed |
| CN-112638914-A | Crystals of pyrazolo [3,4-d ] pyrimidine | 大鹏药品工业株式会社 | 2021-04-09 | — | — | CN | claimed |
| CN-108349981-B | Novel pyrazolo [3, 4-d ] pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2021-03-30 | — | — | CN | claimed |
| EP-3345907-B1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS OR SALTS THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2020-04-22 | — | — | EP | claimed |
| US-20200061067-A1 | AGENT ENHANCING ANTITUMOR EFFECT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-02-27 | — | — | US | claimed |
| US-10329300-B2 | Pyrazolo[3,4-d]pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-06-25 | — | — | US | claimed |
| US-20180201615-A1 | PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO. , LTD. (JP) | 2018-07-19 | — | — | US | claimed |
| EP-3345907-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-07-11 | — | — | EP | claimed |
| US-9920060-B2 | Pyrazolo[3,4-d]pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-03-20 | — | — | US | claimed |
| US-20170217970-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | claimed |
| EP-3590516-B1 | ANTITUMOR-EFFECT ENHANCER USING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2025-09-03 | — | — | EP | disclosed |
| EP-3845537-B1 | CRYSTAL OF PYRAZOLO[3,4-D]PYRIMIDINE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2025-07-30 | — | — | EP | disclosed |
| US-12215109-B2 | Crystal of pyrazolo[3,4-d]pyrimidine | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-02-04 | — | — | US | disclosed |
| US-12215109-B2 | Crystal of pyrazolo[3,4-d]pyrimidine | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-02-04 | — | — | US | disclosed |
| US-12186320-B2 | Therapeutic agent containing pyrazolo[3,4-d]pyrimidine compound as active ingredient | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-01-07 | — | — | US | disclosed |
| EP-3845231-B1 | THERAPEUTIC AGENT CONTAINING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | TAIHO PHARMACEUTICAL CO LTD (JP) | 2025-01-01 | — | — | EP | disclosed |
| US-20230295167-A1 | POTENT AND SELECTIVE INHIBITORS OF HER2 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11696917-B2 | Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-07-11 | — | — | US | disclosed |
| CN-113336760-B | Substituted amide derivatives, compositions and uses thereof | 深圳市塔吉瑞生物医药有限公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20210332056-A1 | CRYSTAL OF PYRAZOLO[3,4-D]PYRIMIDINE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-10-28 | — | — | US | disclosed |
| US-20210332056-A1 | CRYSTAL OF PYRAZOLO[3,4-D]PYRIMIDINE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-10-28 | — | — | US | disclosed |
| US-20210332056-A1 | CRYSTAL OF PYRAZOLO[3,4-D]PYRIMIDINE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-10-28 | — | — | US | disclosed |
| CN-113336760-A | Substituted amide derivatives, compositions and uses thereof | 深圳市塔吉瑞生物医药有限公司 | 2021-09-03 | — | — | CN | disclosed |
| US-20210252000-A1 | THERAPEUTIC AGENT CONTAINING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-08-19 | — | — | US | disclosed |
| EP-3845537-A1 | CRYSTAL OF PYRAZOLO[3,4-D]PYRIMIDINE | Taiho Pharmaceutical Co., Ltd. (JP) | 2021-07-07 | — | — | EP | disclosed |
| EP-3845231-A1 | THERAPEUTIC AGENT CONTAINING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2021-07-07 | — | — | EP | disclosed |
| EP-3845537-A1 | CRYSTAL OF PYRAZOLO[3,4-D]PYRIMIDINE | Taiho Pharmaceutical Co., Ltd. (JP) | 2021-07-07 | — | — | EP | disclosed |
| CN-112638914-A | Crystals of pyrazolo [3,4-d ] pyrimidine | 大鹏药品工业株式会社 | 2021-04-09 | — | — | CN | disclosed |
| CN-112638914-A | Crystals of pyrazolo [3,4-d ] pyrimidine | 大鹏药品工业株式会社 | 2021-04-09 | — | — | CN | disclosed |
| CN-108349981-B | Novel pyrazolo [3, 4-d ] pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2021-03-30 | — | — | CN | disclosed |
| EP-3345907-B1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS OR SALTS THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2020-04-22 | — | — | EP | disclosed |
| WO-2020045475-A1 | CRYSTAL OF PYRAZOLO[3,4-D]PYRIMIDINE | 大鵬薬品工業株式会社 | 2020-03-05 | — | — | WO | disclosed |
| US-20200061067-A1 | AGENT ENHANCING ANTITUMOR EFFECT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-02-27 | — | — | US | disclosed |
| US-10329300-B2 | Pyrazolo[3,4-d]pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-06-25 | — | — | US | disclosed |
| US-20180201615-A1 | PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO. , LTD. (JP) | 2018-07-19 | — | — | US | disclosed |
| EP-3345907-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-07-11 | — | — | EP | disclosed |
| US-9920060-B2 | Pyrazolo[3,4-d]pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-03-20 | — | — | US | disclosed |
| US-20170217970-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170217970-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12215109-B2 | Crystal of pyrazolo[3,4-d]pyrimidine | NLRP1, P2RX4, P2RX5 | ERBB2 1321/4885EGFR 2449/4885JAK3 240/4885 |
| US-20210252000-A1 | THERAPEUTIC AGENT CONTAINING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | ERBB2, TP53, TK1 | ERBB2 1/4885EGFR 6/4885JAK3 1080/4885 |
| US-20170217970-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | ERBB2, JAK2, ERBB4 | ERBB2 1/4885EGFR 7/4885JAK3 19/4885 |
| US-11696917-B2 | Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound | ZYX, DPYD, ZFX | ERBB2 2137/4885EGFR 2082/4885JAK3 196/4885 |
| US-20230295167-A1 | POTENT AND SELECTIVE INHIBITORS OF HER2 | ERBB2, EGFR, ERBB3 | ERBB2 1/4885EGFR 2/4885JAK3 946/4885 |
| US-20210332056-A1 | CRYSTAL OF PYRAZOLO[3,4-D]PYRIMIDINE | NLRP1, P2RX4, P2RX5 | ERBB2 1321/4885EGFR 2449/4885JAK3 240/4885 |
| US-20180201615-A1 | PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | ERBB2, JAK2, ERBB4 | ERBB2 1/4885EGFR 5/4885JAK3 15/4885 |
| US-12186320-B2 | Therapeutic agent containing pyrazolo[3,4-d]pyrimidine compound as active ingredient | ERBB2, TP53, TK1 | ERBB2 1/4885EGFR 6/4885JAK3 1080/4885 |
| US-10329300-B2 | Pyrazolo[3,4-d]pyrimidine compound or salt thereof | ERBB2, JAK2, ERBB4 | ERBB2 1/4885EGFR 5/4885JAK3 15/4885 |
| US-20200061067-A1 | AGENT ENHANCING ANTITUMOR EFFECT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND | ZYX, DPYD, ZFX | ERBB2 2137/4885EGFR 2082/4885JAK3 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.